Skip to main content
Top
Published in: BMC Medical Genetics 1/2019

Open Access 01-12-2019 | Cardiomyopathy | Research article

Clinical course, mutations and its functional characteristics of infantile-onset Pompe disease in Thailand

Authors: Lukana Ngiwsara, Duangrurdee Wattanasirichaigoon, Thipwimol Tim-Aroon, Kitiwan Rojnueangnit, Saisuda Noojaroen, Arthaporn Khongkraparn, Phannee Sawangareetrakul, James R. Ketudat-Cairns, Ratana Charoenwattanasatien, Voraratt Champattanachai, Chulaluck Kuptanon, Suthipong Pangkanon, Jisnuson Svasti

Published in: BMC Medical Genetics | Issue 1/2019

Login to get access

Abstract

Background

Pompe disease is a lysosomal storage disorder caused by the deficiency of acid alpha-glucosidase (EC. 3.2.1.20) due to mutations in human GAA gene. The objective of the present study was to examine clinical and molecular characteristics of infantile-onset Pompe disease (IOPD) in Thailand.

Methods

Twelve patients with infantile-onset Pompe disease (IOPD) including 10 Thai and two other Asian ethnicities were enrolled. To examine the molecular characteristics of Pompe patients, GAA gene was analyzed by PCR amplification and direct Sanger-sequencing of 20 exons coding region. The novel mutations were transiently transfected in COS-7 cells for functional verification. The severity of the mutation was rated by study of the GAA enzyme activity detected in transfected cells and culture media, as well as the quantity and quality of the proper sized GAA protein demonstrated by western blot analysis. The GAA three dimensional structures were visualized by PyMol software tool.

Results

All patients had hypertrophic cardiomyopathy, generalized muscle weakness, and undetectable or < 1% of GAA normal activity. Three patients received enzyme replacement therapy with variable outcome depending on the age of the start of enzyme replacement therapy (ERT). Seventeen pathogenic mutations including four novel variants: c.876C > G (p.Tyr292X), c.1226insG (p.Asp409GlyfsX95), c.1538G > A (p.Asp513Gly), c.1895 T > G (p.Leu632Arg), and a previously reported rare allele of unknown significance: c.781G > A (p.Ala261Thr) were identified. The rating system ranked p.Tyr292X, p. Asp513Gly and p. Leu632Arg as class “B” and p. Ala261Thr as class “D” or “E”. These novel mutations were located in the N-terminal beta-sheet domain and the catalytic domain.

Conclusions

The present study provides useful information on the mutations of GAA gene in the underrepresented population of Asia which are more diverse than previously described and showing the hotspots in exons 14 and 5, accounting for 62% of mutant alleles. Almost all mutations identified are in class A/B. These data can benefit rapid molecular diagnosis of IOPD and severity rating of the mutations can serve as a partial substitute for cross reactive immunological material (CRIM) study.
Literature
1.
go back to reference Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, et al. Pompe disease diagnosis and management guideline. Genet Med. 2006;8(5):267–88.CrossRef Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, et al. Pompe disease diagnosis and management guideline. Genet Med. 2006;8(5):267–88.CrossRef
2.
go back to reference van den Hout HM, Hop W, van Diggelen OP, Smeitink JA, Smit GP, Poll-The BT, et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics. 2003;112(2):332–40.CrossRef van den Hout HM, Hop W, van Diggelen OP, Smeitink JA, Smit GP, Poll-The BT, et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics. 2003;112(2):332–40.CrossRef
3.
go back to reference Leslie N, Bailey L. Pompe disease. GeneReviews® [Internet]. M.P. Adam, H.H. Ardinger, R.A. Pagon, et al., editors.Seattle (WA), University of Washington, Seattle,1993-2018. Initial Posting: August 31, 2007, Last Update: May 11, 2017. Leslie N, Bailey L. Pompe disease. GeneReviews® [Internet]. M.P. Adam, H.H. Ardinger, R.A. Pagon, et al., editors.Seattle (WA), University of Washington, Seattle,1993-2018. Initial Posting: August 31, 2007, Last Update: May 11, 2017.
4.
go back to reference Angelini C, Semplicini C. Enzyme replacement therapy for Pompe disease. Curr Neurol Neurosci Rep. 2011;12:70–5.CrossRef Angelini C, Semplicini C. Enzyme replacement therapy for Pompe disease. Curr Neurol Neurosci Rep. 2011;12:70–5.CrossRef
5.
go back to reference Hirschhorn R. Glycogen storage disease type II: acid alpha-glucosidase (acid maltose) deficiency. In: Scriver CR, editor. The Metabolicand Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill; 2001. p. 3389–420. Hirschhorn R. Glycogen storage disease type II: acid alpha-glucosidase (acid maltose) deficiency. In: Scriver CR, editor. The Metabolicand Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill; 2001. p. 3389–420.
6.
go back to reference Hoefsloot LH, Hoogeveen-Westerveld M, Reuser AJ, Oostra BA. Characterization of the human lysosomal alpha-glucosidase gene. Biochem J. 1990;272(2):493–7.CrossRef Hoefsloot LH, Hoogeveen-Westerveld M, Reuser AJ, Oostra BA. Characterization of the human lysosomal alpha-glucosidase gene. Biochem J. 1990;272(2):493–7.CrossRef
7.
go back to reference Martiniuk F, Bodkin M, Tzall S, Hirschhorn R. Isolation and partial characterization of the structural gene for human acid alpha glucosidase. DNA Cell Biol. 1991;10(4):283–92.CrossRef Martiniuk F, Bodkin M, Tzall S, Hirschhorn R. Isolation and partial characterization of the structural gene for human acid alpha glucosidase. DNA Cell Biol. 1991;10(4):283–92.CrossRef
8.
go back to reference Moreland RJ, Jin X, Zhang XK, Decker RW, Albee KL, Lee KL, et al. Lysosomal acid alpha-glucosidase consists of four different peptides processed from a single chain precursor. J Biol Chem. 2005;280(8):6780–91.CrossRef Moreland RJ, Jin X, Zhang XK, Decker RW, Albee KL, Lee KL, et al. Lysosomal acid alpha-glucosidase consists of four different peptides processed from a single chain precursor. J Biol Chem. 2005;280(8):6780–91.CrossRef
9.
go back to reference Wisselaar HA, Kroos MA, Hermans MM, van Beeumen J, Reuser AJ. Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation. J Biol Chem. 1993;268(3):2223–31.PubMed Wisselaar HA, Kroos MA, Hermans MM, van Beeumen J, Reuser AJ. Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation. J Biol Chem. 1993;268(3):2223–31.PubMed
11.
go back to reference Kroos M, Pomponio RJ, van Vliet L, Palmer RE, Phipps M, Van der Helm R, et al. GAA Database Consortium. Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating. Hum Mutat. 2008;29:E13–26.CrossRef Kroos M, Pomponio RJ, van Vliet L, Palmer RE, Phipps M, Van der Helm R, et al. GAA Database Consortium. Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating. Hum Mutat. 2008;29:E13–26.CrossRef
12.
go back to reference Kroos M, Hoogeveen-Westerveld M, Michelakakis H, Pomponio R, Van der Ploeg A, Halley D, et al. GAA Database Consortium. Update of the pompe disease mutation database with 60 novel GAA sequence variants and additional studies on the functional effect of 34 previously reported variants. Hum Mutat. 2012;33:1161–5.CrossRef Kroos M, Hoogeveen-Westerveld M, Michelakakis H, Pomponio R, Van der Ploeg A, Halley D, et al. GAA Database Consortium. Update of the pompe disease mutation database with 60 novel GAA sequence variants and additional studies on the functional effect of 34 previously reported variants. Hum Mutat. 2012;33:1161–5.CrossRef
13.
go back to reference Hermans MM, de Graaff E, Kroos MA, Wisselaar HA, Willemsen R, Oostra BA, et al. The conservative substitution Asp-645>Glu in lysosomal alpha-glucosidase affects transport and phosphorylation of the enzyme in an adult patient with glycogen-storage disease type II. Biochem J. 1993;289:687–93.CrossRef Hermans MM, de Graaff E, Kroos MA, Wisselaar HA, Willemsen R, Oostra BA, et al. The conservative substitution Asp-645>Glu in lysosomal alpha-glucosidase affects transport and phosphorylation of the enzyme in an adult patient with glycogen-storage disease type II. Biochem J. 1993;289:687–93.CrossRef
14.
go back to reference Hermans MM, Kroos MA, van Beeumen J, Oostra BA, Reuser AJ. Human lysosomal alpha-glucosidase. Characterization of the catalytic site. J Biol Chem. 1991;266(21):13507–12.PubMed Hermans MM, Kroos MA, van Beeumen J, Oostra BA, Reuser AJ. Human lysosomal alpha-glucosidase. Characterization of the catalytic site. J Biol Chem. 1991;266(21):13507–12.PubMed
15.
go back to reference Lin CY, Shieh JJ. Identification of a de Novo point mutation resulting in infantile form of Pompe's disease. Biochem Biophys Res Commun. 1995;213(1):367.CrossRef Lin CY, Shieh JJ. Identification of a de Novo point mutation resulting in infantile form of Pompe's disease. Biochem Biophys Res Commun. 1995;213(1):367.CrossRef
16.
go back to reference Palmer RE, Amartino HM, Niizawa G, Blanco M, Pomponio RJ, Chamoles NA. Pompe disease (glycogen storage disease type II) in Argentineans: clinical manifestations and identification of 9 novel mutations. Neuromuscul Disord. 2007;17(1):16–22.CrossRef Palmer RE, Amartino HM, Niizawa G, Blanco M, Pomponio RJ, Chamoles NA. Pompe disease (glycogen storage disease type II) in Argentineans: clinical manifestations and identification of 9 novel mutations. Neuromuscul Disord. 2007;17(1):16–22.CrossRef
17.
go back to reference Huie ML, Tsujino S, Sklower Brooks S, Engel A, Elias E, Bonthron DT, et al. Glycogen storage disease type II: identification of four novel missense mutations (D645N, G648S, R672W, R672Q) and two insertions/deletions in the acid alpha-glucosidase locus of patients of differing phenotype. Biochem Biophys Res Commun. 1998;244(3):921–7.CrossRef Huie ML, Tsujino S, Sklower Brooks S, Engel A, Elias E, Bonthron DT, et al. Glycogen storage disease type II: identification of four novel missense mutations (D645N, G648S, R672W, R672Q) and two insertions/deletions in the acid alpha-glucosidase locus of patients of differing phenotype. Biochem Biophys Res Commun. 1998;244(3):921–7.CrossRef
18.
go back to reference Wan L, Lee CC, Hsu CM, Hwu WL, Yang CC, Tsai CH, et al. Identification of eight novel mutations of the acid alpha-glucosidase gene causing the infantile or juvenile form of glycogen storage disease type II. J Neurol. 2008;255(6):831–8.CrossRef Wan L, Lee CC, Hsu CM, Hwu WL, Yang CC, Tsai CH, et al. Identification of eight novel mutations of the acid alpha-glucosidase gene causing the infantile or juvenile form of glycogen storage disease type II. J Neurol. 2008;255(6):831–8.CrossRef
19.
go back to reference Bali DS, Goldstein JL, Banugaria S, Dai J, Mackey J, Rehder C, et al. Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: Lessons learned from 10 years of clinical laboratory testing experience. Am J Med Genet C: Semin Med Genet. 2012;160c(1):40–9.CrossRef Bali DS, Goldstein JL, Banugaria S, Dai J, Mackey J, Rehder C, et al. Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: Lessons learned from 10 years of clinical laboratory testing experience. Am J Med Genet C: Semin Med Genet. 2012;160c(1):40–9.CrossRef
20.
go back to reference Zampieri S, Buratti E, Dominissini S, Montalvo AL, Pittis MG, Bembi B, et al. Splicing mutations in glycogen-storage disease type II: evaluation of the full spectrum of mutations and their relation to patients' phenotypes. Eur J Hum Genet. 2011;19(4):422–31.CrossRef Zampieri S, Buratti E, Dominissini S, Montalvo AL, Pittis MG, Bembi B, et al. Splicing mutations in glycogen-storage disease type II: evaluation of the full spectrum of mutations and their relation to patients' phenotypes. Eur J Hum Genet. 2011;19(4):422–31.CrossRef
21.
go back to reference van der Kraan M, Kroos MA, Joosse M, Bijvoet AG, Verbeet MP, Kleijer WJ, et al. Deletion of exon 18 is a frequent mutation in glycogen storage disease type II. Biochem Biophys Res Commun. 1994;203:1535–41.CrossRef van der Kraan M, Kroos MA, Joosse M, Bijvoet AG, Verbeet MP, Kleijer WJ, et al. Deletion of exon 18 is a frequent mutation in glycogen storage disease type II. Biochem Biophys Res Commun. 1994;203:1535–41.CrossRef
22.
go back to reference Shieh JJ, Lin CY. Frequent mutation in Chinese patients with infantile type of GSD II in Taiwan: evidence for a founder effect. Hum Mutat. 1998;11(4):306–12.CrossRef Shieh JJ, Lin CY. Frequent mutation in Chinese patients with infantile type of GSD II in Taiwan: evidence for a founder effect. Hum Mutat. 1998;11(4):306–12.CrossRef
23.
go back to reference Hermans MM, van Leenen D, Kroos MA, Beesley CE, Van Der Ploeg AT, Sakuraba H, et al. Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II. Hum Mutat. 2004;23(1):47–56.CrossRef Hermans MM, van Leenen D, Kroos MA, Beesley CE, Van Der Ploeg AT, Sakuraba H, et al. Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II. Hum Mutat. 2004;23(1):47–56.CrossRef
24.
go back to reference Montalvo AL, Bembi B, Donnarumma M, Filocamo M, Parenti G, Rossi M, et al. Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II. Hum Mutat. 2006;27(10):999–1006.CrossRef Montalvo AL, Bembi B, Donnarumma M, Filocamo M, Parenti G, Rossi M, et al. Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II. Hum Mutat. 2006;27(10):999–1006.CrossRef
25.
go back to reference Ngiwsara L, Ketudat-Cairns JR, Sawangareetrakul P, Charoenwattanasatien R, Champattanachai V, Kuptanon C, et al. p.X654R IDUA variant among Thai individuals with intermediate mucopolysaccharidosis type I and its residual activity as demonstrated in COS-7 cells. Ann Hum Genet. 2018;82(3):150–7.CrossRef Ngiwsara L, Ketudat-Cairns JR, Sawangareetrakul P, Charoenwattanasatien R, Champattanachai V, Kuptanon C, et al. p.X654R IDUA variant among Thai individuals with intermediate mucopolysaccharidosis type I and its residual activity as demonstrated in COS-7 cells. Ann Hum Genet. 2018;82(3):150–7.CrossRef
26.
go back to reference Okumiya T, Keulemans JL, Kroos MA, Van der Beek NM, Boer MA, Takeuchi H, et al. A new diagnostic assay for glycogen storage disease type II in mixed leukocytes. Mol Genet Metab. 2006;88(1):22–8.CrossRef Okumiya T, Keulemans JL, Kroos MA, Van der Beek NM, Boer MA, Takeuchi H, et al. A new diagnostic assay for glycogen storage disease type II in mixed leukocytes. Mol Genet Metab. 2006;88(1):22–8.CrossRef
27.
go back to reference Koressaar T, Remm M. Enhancements and modifications of primer design program Primer3. Bioinformatics. 2007;23:1289–91.CrossRef Koressaar T, Remm M. Enhancements and modifications of primer design program Primer3. Bioinformatics. 2007;23:1289–91.CrossRef
28.
go back to reference Roig-Zamboni V, Cobucci-Ponzano B, Iacono R, Ferrara MC, Germany S, Bourne Y, et al. Structure of human lysosomal acid α-glucosidase-a guide for the treatment of Pompe disease. Nat Commun. 2017;8:1111.CrossRef Roig-Zamboni V, Cobucci-Ponzano B, Iacono R, Ferrara MC, Germany S, Bourne Y, et al. Structure of human lysosomal acid α-glucosidase-a guide for the treatment of Pompe disease. Nat Commun. 2017;8:1111.CrossRef
29.
go back to reference Kroos MA, Mullaart RA, Van Vliet L, Pomponio RJ, Amartino H, Kolodny EH, et al. p.[G576S; E689K]: pathogenic combination or polymorphism in Pompe disease? Eur J Hum Genet. 2008;16(8):875–9.CrossRef Kroos MA, Mullaart RA, Van Vliet L, Pomponio RJ, Amartino H, Kolodny EH, et al. p.[G576S; E689K]: pathogenic combination or polymorphism in Pompe disease? Eur J Hum Genet. 2008;16(8):875–9.CrossRef
30.
go back to reference Yang CF, Yang CC, Liao HC, Huang LY, Chiang CC, Ho HC, et al. Very Early Treatment for Infantile-Onset Pompe Disease Contributes to Better Outcomes. J Pediatr. 2016;169:174–80.CrossRef Yang CF, Yang CC, Liao HC, Huang LY, Chiang CC, Ho HC, et al. Very Early Treatment for Infantile-Onset Pompe Disease Contributes to Better Outcomes. J Pediatr. 2016;169:174–80.CrossRef
31.
go back to reference Chien YH, Lee NC, Thurberg BL, Chiang SC, Zhang XK, Keutzer J, et al. Pompe disease in infants: improving the prognosis by newborn screening and early treatment. Pediatrics. 2009;124:E1116–25.CrossRef Chien YH, Lee NC, Thurberg BL, Chiang SC, Zhang XK, Keutzer J, et al. Pompe disease in infants: improving the prognosis by newborn screening and early treatment. Pediatrics. 2009;124:E1116–25.CrossRef
32.
go back to reference Amarinthnukrowh P, Tongkobpetch S, Kongpatanayothin A, Suphapeetiporn K, Shotelersuk V. p.D645E of acid α-glucosidase is the most common mutation in thai patients with infantile-onset pompe disease. Genet Test Mol Biomarkers. 2010;14:835–7.CrossRef Amarinthnukrowh P, Tongkobpetch S, Kongpatanayothin A, Suphapeetiporn K, Shotelersuk V. p.D645E of acid α-glucosidase is the most common mutation in thai patients with infantile-onset pompe disease. Genet Test Mol Biomarkers. 2010;14:835–7.CrossRef
33.
go back to reference Fukuhara Y, Fuji N, Yamazaki N, Hirakiyama A, Kamioka T, Seo JH, et al. A molecular analysis of the GAA gene and clinical spectrum in 38 patients with Pompe disease in Japan. Mol Genet Metab Rep. 2017;14:3–9.CrossRef Fukuhara Y, Fuji N, Yamazaki N, Hirakiyama A, Kamioka T, Seo JH, et al. A molecular analysis of the GAA gene and clinical spectrum in 38 patients with Pompe disease in Japan. Mol Genet Metab Rep. 2017;14:3–9.CrossRef
34.
go back to reference Huie ML, Chen AS, Brooks SS, Grix A, Hirschhorn R. A de novo 13 nt deletion, a newly identified C647W missense mutation and a deletion of exon 18 in infantile onset glycogen storage disease type II (GSDII). Hum Mol Genet. 1994;3:1081–7.CrossRef Huie ML, Chen AS, Brooks SS, Grix A, Hirschhorn R. A de novo 13 nt deletion, a newly identified C647W missense mutation and a deletion of exon 18 in infantile onset glycogen storage disease type II (GSDII). Hum Mol Genet. 1994;3:1081–7.CrossRef
35.
go back to reference Fernandez-Hojas R, Huie ML, Navarro C, Dominguez C, Roig M, Lopez-Coronas D, et al. Identification of six novel mutations in the acid alpha-glucosidase gene in three Spanish patients with infantile onset glycogen storage disease type II (Pompe disease). Neuromuscul Disord. 2002;12:159–66 Erratum in: Neuromuscul Disord 13 (2003) 427.CrossRef Fernandez-Hojas R, Huie ML, Navarro C, Dominguez C, Roig M, Lopez-Coronas D, et al. Identification of six novel mutations in the acid alpha-glucosidase gene in three Spanish patients with infantile onset glycogen storage disease type II (Pompe disease). Neuromuscul Disord. 2002;12:159–66 Erratum in: Neuromuscul Disord 13 (2003) 427.CrossRef
Metadata
Title
Clinical course, mutations and its functional characteristics of infantile-onset Pompe disease in Thailand
Authors
Lukana Ngiwsara
Duangrurdee Wattanasirichaigoon
Thipwimol Tim-Aroon
Kitiwan Rojnueangnit
Saisuda Noojaroen
Arthaporn Khongkraparn
Phannee Sawangareetrakul
James R. Ketudat-Cairns
Ratana Charoenwattanasatien
Voraratt Champattanachai
Chulaluck Kuptanon
Suthipong Pangkanon
Jisnuson Svasti
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Medical Genetics / Issue 1/2019
Electronic ISSN: 1471-2350
DOI
https://doi.org/10.1186/s12881-019-0878-8

Other articles of this Issue 1/2019

BMC Medical Genetics 1/2019 Go to the issue